» Articles » PMID: 25663413

Prevalence and Incidence of Cognitive Impairment in Multiple Sclerosis: a Population-based Survey in Catania, Sicily

Overview
Journal J Neurol
Specialty Neurology
Date 2015 Feb 10
PMID 25663413
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Cognitive impairment (CIm) is a frequent finding in multiple sclerosis (MS) affecting up to 65% of patients. The aim of this study was to evaluate the prevalence and incidence of CIm in a population-based cohort of MS patients identified in the city of Catania from 1995 to 2004. One-hundred and twenty-five patients experiencing the onset of MS during 1995-2004 were enrolled. Cognitive performance was assessed through the Brief Repeatable Battery (BRB) of neuropsychological tests and the Stroop word-color task (ST). CIm was defined as the failure on at least three tests involving at least two different domains. Patients without CIm at baseline were followed up after over 3 years. The most impaired tests were the Symbol Digit Modalities Test (36%) and the Paced Auditory Serial Addition Test 3 (35%). At baseline the prevalence of CIm was 44% (95% CI 35.2-53.1). An almost sixfold increased risk of developing CIm was found among MS patients aged 40 and above at the time of the NPS examination (OR 5.84; 95% CI 2.57-13.2; p value <0.0001) and a threefold increased risk for patients with an EDSS score >3 (OR 3.51; 95% CI 1.30-9.46, p value 0.01). At the follow-up out of the 70 MS patients without CIm at baseline evaluation, 26 (37.1 %) developed CIm. The total person-years at risk was 269 person-years giving an incidence rate of CIm of 96.6/1,000 person-year (95% CI 57.3-128.7). The overall prevalence of CIm in MS is 44% and the incidence after 4 years is 37.1%. CIm affects more frequently patients older than 40 years and with a higher EDSS score.

Citing Articles

Mapping cognitive dysfunction in relapsing multiple sclerosis with mild disability: A cross-sectional study from South India.

Nair S, Thulaseedharan J, Rajan N, Bava E, Nair G, Sundaram S Mult Scler J Exp Transl Clin. 2024; 10(4):20552173241304302.

PMID: 39676817 PMC: 11639032. DOI: 10.1177/20552173241304302.


NEDA-state, psychological symptoms and quality of life are stable in natalizumab-treated multiple sclerosis patients: An up to 6-years long follow-up study.

Sandi D, Kokas Z, Kincses Z, Fuvesi J, Fricska-Nagy Z, Voros E Heliyon. 2024; 10(20):e39536.

PMID: 39502229 PMC: 11535987. DOI: 10.1016/j.heliyon.2024.e39536.


Prevalence of cognitive impairment (CI) in patients with multiple sclerosis (MS): A systematic review and meta-analysis.

Askari M, Mirmosayyeb O, Fattahi F, Ghoshouni H, Moases Ghaffary E, Shaygannejad V Caspian J Intern Med. 2024; 15(3):392-413.

PMID: 39011445 PMC: 11246688. DOI: 10.22088/cjim.15.3.392.


Cognitive impairment in multiple sclerosis: from phenomenology to neurobiological mechanisms.

Jellinger K J Neural Transm (Vienna). 2024; 131(8):871-899.

PMID: 38761183 DOI: 10.1007/s00702-024-02786-y.


The 7-year follow-up of the Hungarian BICAMS validation cohort implies that cognitive performance may improve in multiple sclerosis patients.

Nyari A, Kokas Z, Szamosi S, Fricska-Nagy Z, Fuvesi J, Kincses Z Neurol Sci. 2024; 45(7):3369-3378.

PMID: 38280085 DOI: 10.1007/s10072-024-07347-5.


References
1.
Patti F . Cognitive impairment in multiple sclerosis. Mult Scler. 2008; 15(1):2-8. DOI: 10.1177/1352458508096684. View

2.
Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin L, Tommasi M . A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001; 70(6):773-80. PMC: 1737379. DOI: 10.1136/jnnp.70.6.773. View

3.
Potagas C, Giogkaraki E, Koutsis G, Mandellos D, Tsirempolou E, Sfagos C . Cognitive impairment in different MS subtypes and clinically isolated syndromes. J Neurol Sci. 2007; 267(1-2):100-6. DOI: 10.1016/j.jns.2007.10.002. View

4.
Barbarotto R, Laiacona M, Frosio R, Vecchio M, Farinato A, Capitani E . A normative study on visual reaction times and two Stroop colour-word tests. Ital J Neurol Sci. 2000; 19(3):161-70. DOI: 10.1007/BF00831566. View

5.
Patti F, Morra V, Amato M, Trojano M, Bastianello S, Tola M . Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One. 2013; 8(8):e74111. PMC: 3796707. DOI: 10.1371/journal.pone.0074111. View